MicroRNAs in metabolic dysfunction‐associated diseases: Pathogenesis and therapeutic opportunities

Abstract Metabolic dysfunction‐associated diseases often refer to various diseases caused by metabolic problems such as glucose and lipid metabolism disorders. With the improvement of living standards, the increasing prevalence of metabolic diseases has become a severe public health problem, including metabolic dysfunction‐associated steatotic liver disease (MASLD), alcohol‐related liver disease (ALD), diabetes and obesity. These diseases are both independent and interdependent, with complex and diverse molecular mechanisms. Therefore, it is urgent to explore the molecular mechanisms and find effective therapeutic targets of these diseases. MicroRNAs (miRNAs) have emerged as key regulators of metabolic homoeostasis due to their multitargets and network regulatory properties within the past few decades. In this review, we discussed the latest progress in the roles of miRNA‐mediated regulatory networks in the development and progression of MASLD, ALD, diabetes and obesity.